Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.

ABSTRACT: Immunotherapies directly enhancing anti-tumor CD8⁺ T cell responses have yielded measurable but limited success, highlighting the need for alternatives. Anti-tumor T cell responses critically depend on antigen presenting dendritic cells (DC), and enhancing mobilization, antigen loading and activation of these cells represent an attractive possibility to potentiate T cell based therapies. Here we show that expansion of DCs by Flt3L administration impacts in situ vaccination with oncolytic Newcastle Disease Virus (NDV). Mechanistically, NDV activates DCs and sensitizes them to dying tumor cells through upregulation of dead-cell receptors and synergizes with Flt3L to promote anti-tumor CD8⁺ T cell cross-priming. In vivo, Flt3L-NDV in situ vaccination induces parallel amp

SUBMITTER: Svensson-Arvelund J 

PROVIDER: S-EPMC9684150 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature